Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.

Détails

ID Serval
serval:BIB_9D3435B5BCAB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
Périodique
Klinische Monatsblätter für Augenheilkunde
Auteur⸱e⸱s
Petropoulos I.K., Vaudaux J.D., Guex-Crosier Y.
ISSN
0023-2165
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
225
Numéro
5
Pages
457-61
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article - Publication Status: ppublish
Résumé
BACKGROUND: The purpose of this study is to describe the experience of Jules Gonin Eye Hospital on the long-term outcome of anti-TNF-alpha therapy in chronic non-infectious uveitis. PATIENTS AND METHODS: We identified and followed those patients with chronic non-infectious uveitis who received systemic anti-TNF-alpha therapy. Anti-TNF-alpha therapy was administered when no response had been obtained with classical immunosuppressive therapies or in the presence of severe rheumatoid disease. RESULTS: Fifteen patients (28 eyes), 7 male and 8 female (mean age, 43 years; range: 7 to 70 years) were identified. Diagnoses included HLA-B27-associated anterior uveitis (n = 4), sarcoidosis (n = 2), juvenile idiopathic arthritis (n = 2), idiopathic retinal vasculitis with uveitis (n = 2), pars planitis (n = 2), Adamantiades-Behçet disease (n = 1), birdshot retinochoroidopathy (n = 1), and Crohn's disease (n = 1). Mean duration of ocular disease was 8 years (range: 1 to 29 years). Treatment with infliximab (n = 11), etanercept (n = 2), or adalimumab (n = 2) was initiated. One patient with etanercept was switched to infliximab due to lack of clinical response. Clinical and angiographic regression of uveitis was observed within the first two months of therapy in all patients, and was maintained throughout the entire follow-up period (mean 18 months; range: 3 - 72 months). Recurrence was observed in 3 patients, and resolved after adjustment of therapy. Adverse events were recorded in only one patient (arterial hypotension). CONCLUSIONS: In this series of patients with chronic non-infectious uveitis, anti-TNF-alpha therapy was effective and safe. Further clinical studies are needed to determine an adequate duration of therapy.
Mots-clé
Adolescent, Adult, Aged, Anti-Inflammatory Agents, Child, Eye Infections, Female, Humans, Male, Middle Aged, Switzerland, Treatment Outcome, Tumor Necrosis Factor-alpha, Uveitis
Pubmed
Web of science
Création de la notice
28/03/2009 16:52
Dernière modification de la notice
20/08/2019 16:03
Données d'usage